Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Leelamine Blocks Melanoma Growth by Disrupting Cellular Cholesterol Transport

By BiotechDaily International staff writers
Posted on 03 Jun 2014
An experimental chemotherapeutic drug interferes with intracellular cholesterol transport, which kills melanoma cells by disrupting several molecular pathways simultaneously.

The drug, leelamine, which is a natural compound isolated from pine bark, is a diterpene compound and a weak agonist of the cannabinoid CB1 receptor. The structure of leelamine contains no binding oxygen atoms, underscoring its weak association with the CB1 binding site. Leelamine has been reported to inhibit PDK (pyruvate dehydrogenase kinase) activity.

The PI3 kinase (PI3K), MAP kinase (MAPK), and STAT3 molecular pathways promote disease development by being constitutively activated in 50%–70% of melanomas. To identify a drug capable of simultaneously targeting the PI3K, MAPK, and STAT3 cascades, investigators at the Pennsylvania State University (Hershey, USA) screened 480 compounds from a natural product library. Leelamine was identified as the best potential inhibitor.

Results published in the March 31, 2014, online edition of the journal Molecular Cancer Therapeutics revealed that leelamine inhibited the growth of preexisting xenografted melanoma tumors by an average of 60% by targeting the PI3K, MAPK, and STAT3 pathways without affecting animal body weight or blood markers of major organ function. The mechanism of action of leelamine was mediated by disruption of cholesterol transport, causing decreased cellular proliferation and, consequently leading to increased tumor cell apoptosis as well as decreased tumor vascularization.

"Natural products can be a source of effective cancer drugs, and several are being used for treating a variety of cancers," said senior author Dr. Gavin Robertson, professor of pharmacology, pathology, dermatology, and surgery at The Pennsylvania State University. "Over 60% of anticancer agents are derived from plants, animals, marine sources. or microorganisms. However, leelamine is unique in the way that it acts. To a cancer cell, resistance is like a traffic problem in its circuitry. Cancer cells see treatment with a single drug as a road closure and use a detour or other roads to bypass the closure. The cancer cell is addicted to these pathways, and when they are shut down, the bypass routes cannot be used. The result is the cancer cells die."

Related Links:

The Pennsylvania State University



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Diagram illustrates the innovative process that could lead to more effective drugs against influenza infection (Photo courtesy of the Hebrew University of Jerusalem).

Researchers Show How the Influenza Virus Blocks Natural Killer Cell Recognition

A team of molecular virologists has described how the influenza virus evolved a defense mechanism to protect it from attack by the immune system's natural killer (NK) cells. The recognition of pathogen-infected... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

Genome-Wide Mutation-Searching Computational Software Designed for Genomic Medicine

Analysis software cross-references a patient’s symptoms with his genome sequence to help physicians in the diagnosis of disease. This software was created by a team of scientists from A*STAR’s Genome Institute of Singapore (GIS), led by Dr. Pauline Ng. The research findings were published August 3, 2014, in the journal... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.